Sir Run Run Shaw Hospital

This study enrolls CAD patients with EA confirmed by IVUS at multiple centers, including Sir Run Run Shaw Hospital. Inclusion criteria include age ≥ 18, tolerating dual antiplatelet therapy, lesion length ≥ 20 mm, and understanding of trial content. Exclusion criteria cover positive cTnI, CABG lesion, CTO, in-stent restenosis, severe calcification, LMCAD, intervention of > 1 major coronary artery branch, side branch occlusion, cardiogenic shock, and vulnerable populations. Participants are randomly assigned to an intervention group (TNK) or control group (0.9% NaCl), both receiving standard pharmacological treatments. Primary outcome is the incidence of PCI-related MI, defined by high-sensitivity cTnI increase > 5 times the 99th percentile URL within 48 h post-PCI. Secondary outcomes include elevated postoperative high-sensitivity cTnI, slow-flow incidence, frame count, and MACE. Recruitment begins in August 2024 and continues until August 2025.